key: cord-0932440-hhjpjucc
authors: Decramer, Marc; Janssens, Wim; Miravitlles, Marc
title: Chronic obstructive pulmonary disease
date: 2012-04-13
journal: The Lancet
DOI: 10.1016/s0140-6736(11)60968-9
sha: 7c143e4d83d1094cda344d4491592ccae5ee6de9
doc_id: 932440
cord_uid: hhjpjucc

Summary Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. The main cause is smoking tobacco, but other factors have been identified. Several pathobiological processes interact on a complex background of genetic determinants, lung growth, and environmental stimuli. The disease is further aggravated by exacerbations, particularly in patients with severe disease, up to 78% of which are due to bacterial infections, viral infections, or both. Comorbidities include ischaemic heart disease, diabetes, and lung cancer. Bronchodilators constitute the mainstay of treatment: β2 agonists and long-acting anticholinergic agents are frequently used (the former often with inhaled corticosteroids). Besides improving symptoms, these treatments are also thought to lead to some degree of disease modification. Future research should be directed towards the development of agents that notably affect the course of disease.

Chronic obstructive pulmonary disease (COPD) is currently defi ned as "a preventable and treatable disease with some signifi cant extrapulmonary eff ects that may contribute to the severity in individual patients. Its pulmonary component is characterized by airfl ow limitation that is not fully reversible. The airfl ow limitation is usually progressive and associated with an abnormal infl ammatory response of the lung to noxious particles or gases". 1 The general view of this disease is that it will become one of the major health challenges of the next few decades. Prevalence surveys suggest that up to almost a quarter of adults aged 40 years and older have mild airfl ow obstruction. [2] [3] [4] COPD is presently the fourth leading cause of death, but WHO predicts that it will become the third leading cause by 2030; 5 mortality owing to cardiac diseases and stroke decreased over the period 1970-2002, but that of COPD doubled over the same period. 6 In the past two decades important progress has been made in the understanding of the epidemiology, pathophysiology, diagnosis, and treatment of COPD, but important issues remain unresolved. Particular concerns are the causes and mechanisms of disease, mechanisms of infl ammation, whether to diagnose early, identifi cation of eff ective biomarkers, the relation between airway disease and comorbidities, and the development of treatments to increase disease modifi cation. In this Seminar we provide an overview of the insights that have been gained and those that are lacking. We also attempt to defi ne some research questions for the next decade.

Age-adjusted mortality for COPD in the USA doubled from 1970 to 2002, although in other developed countries reports suggest stabilisation of or even falls in the incidence and prevalence. 7, 8 These declines are related to decreases in the prevalence of smoking and reductions in air pollutants. In developing countries prevalence has risen strikingly, owing to increased smoking rates and reductions in other causes of death, particularly from severe infections. Worldwide prevalence of COPD of Global Initiative on Obstructive Lung Disease (GOLD) stage 2 or higher in adults aged 40 years and older is 9-10%. 9 The Burden of Obstructive Lung Disease initiative 2 used standardised methods to investigate the prevalence of COPD around the world and showed important diff erences between countries. Prevalence ranged from 9% in Reykjavik, Iceland, to 22% in Cape Town, South Africa, for men, and from 4% in Hannover, Germany, to 17% in Cape Town for women.

Most prevalence studies use the GOLD defi nition of chronic airfl ow obstruction, for which the threshold is a postbronchodilator ratio of forced expiratory volume in 1 s (FEV₁) to forced vital capacity (also known as the Tiff eneau index) of 0·7. 1 The ratio decreases with age and, therefore, is controversial as an epidemiological tool because its use might lead to overdiagnosis of COPD in elderly patients. 10 Thus, exposure to risk factors and the presence of respiratory symptoms or FEV₁ less than 80% of predicted must also be taken into account. This method of assessment is simple, not tied to reference values derived from complex equations, enables comparison of prevalence estimates across sites, and can be easily understood by patients and the wider population. Four GOLD stages are distinguished on the basis of severity of airfl ow obstruction: stage 1 (mild, FEV₁ ≥80% of predicted) stage 2 (moderate, FEV₁ 50-80% of predicted), stage 3 (severe, FEV₁ 30-50% of predicted), and stage 4 (very severe, FEV₁ <30% of predicted).

Another important feature in the epidemiology of COPD is the high risk of underdiagnosis. 60-85% of patients, mainly with mild to moderate disease, are thought to remain undiagnosed. 11, 12 In a survey in Spain, 10% of adults aged 40-80 years had COPD but in only 27% of them had it previously been diagnosed. 11 The use of spirometry at all levels of health care is crucial to improve diagnosis and detect COPD early. Moreover, although COPD has been typically seen in men, prevalence in women has risen because of the increasing number of those older than 50 years who smoke. For the fi rst time in the USA, similar numbers of men and women died from COPD in the year 2000, although the mortality rate remains lower in women. 13 COPD results from the interplay between genetic susceptibility and exposure to environmental stimuli.

Smoking cigarettes is the main cause, but other causes might increase the risk of and lead to disease in nonsmokers. Maternal smoking, childhood asthma, and child hood respiratory infections are signifi cantly associated with reduced FEV₁, 14 and previous tuberculosis, outdoor air pollution, occupational exposure to dusts and fumes, exposure to second-hand smoke, and biomass smoke inhalation have been particularly associated with the development of airfl ow obstruction and chronic respiratory symptoms. 15 A well established genetic cause of COPD, α₁ antitrypsin defi ciency, is present in 1-2% of individuals with COPD. 16 Genome-wide association studies, however, have identifi ed regions on chromosome 4 near HHIP and in FAM13A and on chromosome 15 in CHRNA and IREB2 that are unequivocally associated with COPD susceptibility. [17] [18] [19] A pooled analysis identifi ed a single-nucleotide polymorphism in MMP12 as a protective factor for COPD. 20 Moreover, several casecontrol studies of candidate genes have linked specifi c loci to phenotypes related to COPD. 21

The principal feature of COPD is limitation of airfl ow that is not fully reversible. Remodelling of the smallairway compartment and loss of elastic recoil by emphysematous destruction of parenchyma result in progressive decline of FEV₁, inadequate lung emptying on expiration, and subsequent static and dynamic hyperinfl ation. 22 At the pathological level, exposure to smoke leads to infi ltration of the mucosa, submucosa, and glandular tissue by infl ammatory cells. Increased mucus content, epithelial-cell hyperplasia, and disturbed tissue repair with wall thickening in the small conducting airways are cardinal features of COPD (fi gure 1). 23 This progressive narrowing, obliteration, and even removal of the terminal bronchioles is accompanied by emphysema, which typically starts in the respiratory bronchioles. 24 The mechanisms that lead to thickening of the small-airway walls and destruction of lung tissue are far from understood, 23 but they are likely to be multifactorial pathobiological processes 25 that are interacting on a complex background of genetic determinants, 26 lung growth, 14 and environmental stimuli (fi gure 2). 3, 13 Within this framework we discuss the pathogenesis of COPD as a progressive immunological disorder. 27 Cigarette smoke causes direct injury of airway epithelial cells, which leads to the release of endogenous intracellular molecules or danger-associated molecular patterns. These signals are identifi ed by pattern-recognition receptors, such as Toll-like receptors 4 and 2 on epithelial cells, and a non-specifi c infl ammatory response is triggered. 28 Upon the release of early cytokines (tumour necrosis factor α and interleukins 1 and 8), macrophages, neutrophils, and dendritic cells are recruited to the site of infl ammation to orchestrate the innate immune response. 29, 30 Proteolytic enzymes and reactive oxygen species are released and, if not suffi ciently counterbalanced by antiproteases and antioxidant factors, further damage will occur. 31 Immature dendritic cells pick up self-antigens released from damaged tissue and foreign antigens from incoming pathogens and present them to naive T cells in the draining lymph nodes. 29 Once activated into T-helper-1 cells, these antigen-specifi c CD4 and CD8 cells and antibody-producing B cells are drawn to the lungs to neutralise the antigens. As the disease progresses, tertiary lymphoid aggregates, including an oligoclonal selection of the B and T cells involved, develop around the small airways. 32, 33 Although the exact nature and function of these aggregates needs to be elucidated, adaptive or autoimmune responses are thought to perpetuate the infl ammation years after smoking cessation. 27, 34 Apart from these basic immunological processes, several other mechanisms might contribute to the infl ammatory cascade. Tapering of the immune response by regulatory T cells protects against uncontrolled infl ammation, 35 and reduced populations of these cells have been seen in the lungs of patients with COPD. 34, 36 By contrast, the numbers of proinfl ammatory T-helper-17 cells rise, 37,38 which suggests impaired immune regulation in COPD. Pulmonary emphysema and cellular ageing share some features: 25, 39 senescence leads to cells becoming non-proliferative but metabolically active, which predisposes individuals to increased infl ammation, reduced cell regeneration, and carcino genesis. Cigarette smoke and oxidative stress promote senescence. 40 As such, COPD can be interpreted as accelerated ageing of the lung, and hence age will increase suscep tibility to COPD. 41 Finally, cellular apoptosis and matrix destruction are continuously compensated for by cellular renewal and matrix repair to maintain lung homoeo stasis. 42 Resident stem cells within the lung are activated by epithelial damage 43 but cigarette smoke limits alveolar repair 44 and dysregulates repair processes involving transforming growth factor β, which leads to fi brosis. 45 The underlying molecular signals are poorly understood, but in COPD repair mechanisms eventually fail. The complexity of the pathogenesis of COPD is refl ected in the broad variation of clinical phenotypes. Further research is needed to clarify to what extent mechanisms off er potential for new targeted inter ventions.

The chronic and progressive course of COPD is frequently aggravated by exacerbations-short periods (at least 48 h) of increased cough, dyspnoea, and production of sputum that can become purulent. Mild exacerbations require increased doses of bronchodilators, moderate exacerbations need treatment with systemic corti costeroids, antibiotics, or both, and severe exacerbations frequently necessitate admission to hospital. Some patients have no or few exacerbations, whereas others have frequent exacerbations. Frequency may increase with increasing severity of COPD. In a systematic review by Hoogendoorn and colleagues, 46 37 studies were identifi ed that defi ned exacerbations according to use of resources. Patients with mild COPD had a mean of 0·82 exacerbations per year, and the rates increased to 1·17, 1·61, and 2·01 in patients with moderate, severe, and very severe disease, respectively. Other characteristics besides severity of COPD are strongly associated with frequent exacerbations, but the best predictor is a history of frequent exacerbations. 47 Exacerbations reduce quality of life, 48 speed disease progression, and increase the risk of death. 49 Because of their impact on the natural history of the disease, a primary goal of treatment is to reduce the number of exacerbations. They are diagnosed on the basis of clinical symptoms. No clear biological markers have been identifi ed. 50 The most promising biomarker so far is amyloid A in serum. In proteomic studies raised concentrations distinguished patients in exacerbated states from those with stable disease and those with severe exacerbations from patients with milder exacerbations. 51 These data require confi rmation in large multicentre studies.

Several causes of exacerbations are suggested for patients with COPD, such as heart failure, pneumonia, pulmonary embolism, non-adherence to inhaled medi cation, or inhalation of irritants, such as tobacco smoke or particles (panel 1). The most frequent cause is viral or bacterial infection. In patients admitted to hospital for COPD exacerbations, viral infections, bacterial infections, or both, were detected in 78% of cases and, more importantly, the exacerbations were more severe than those in patients with non-infectious causes, shown by more marked impairment in lung function and longer times in hospital. 52 The accepted gold standard for the diagnosis of bacterial causes is the isolation of a potentially pathogenic micro-organism in sputum culture. This method, however, is neither sensitive nor specifi c enough to be accurate. Clinical criteria must, therefore, also be taken into account to aid in the decision of whether or not to use antibiotics. The presence of green (purulent) as opposed to white (mucoid) sputum is one of the best and easiest methods of predicting the need for antibiotic therapy. 53, 54 Measurement of procalcitonin concentrations in serum has shown promise as a guide of whether to use antibiotics, 55 although C-reactive protein has shown better results in the prediction of response to antibiotic therapy. 56 Future research will establish the usefulness of both these bio markers in ambulatory patients treated in the community.

An additional diffi culty in the identifi cation of microbial causes for COPD exacerbations is that a substantial proportion of patients with stable disease have bacterial colonisation in the lower airways. Various species colonise the airways, but Haemophilus infl uenzae is most frequently seen. 57 The production of purulent sputum when patients are in a stable state indicates colonisation by potentially pathogenic micro-organisms. 58 Colonising bacteria promote bronchial and systemic infl ammation and release antigens that result in bronchial epithelial injury and facilitate the acquisition of new microbial strains, 59 which is associated with an increased risk of developing an exacerbation. 60 Strain changes for H infl uenzae, Streptococcus pneumoniae, and Moraxella catarrhalis are associated with increased bronchial and systemic infl ammation and the development of exacer bations. 61 Colonising bacteria can, therefore, accelerate the progression of COPD through an increase in the frequency of exacerbations and also through direct injury to the lung tissue (fi gure 3). 59, 62, 63 The type of infecting species depends partly on the severity of the underlying COPD. 64 In mild disease, Immune control S pneumoniae is predominant, whereas in patients with low FEV₁, H infl uenzae and M catarrhalis are more frequently seen. Pseudomonas aeruginosa might be seen in patients with severe obstruction, and acquisition of a new strain is associated with the development of an exacerbation and colonisation of bronchial epithelium. 65 Disease evolution can be worsened without prompt appropriate antibiotic therapy 66 or if a multidrug-resistant strain is present. 67 Some of the risk factors associated with P aeruginosa infection are summarised (panel 2). 64, 68, 69 Viruses are thought to account for 15-25% of all infective exacerbations, particularly human rhinovirus, infl uenza and parainfl uenza viruses, and adenoviruses. Concomitant infection with viruses and bacteria are seen in 25% of patients with exacerbations who are admitted to hospital. 52 Viral exacerbations are strongly correlated with colds at presentation, high frequency of exacerbations, and severe respiratory symptoms during exacerbations. Mallia and co-workers 70 used experimental rhinovirus infection in individuals with COPD and noted the development of lower-airway respiratory symptoms, airfl ow obstruction, systemic infl ammation, and infl ammation of the airways. A signifi cant correlation was also seen between viral load and concentrations of infl ammatory markers. These fi ndings strongly support a causal relation between rhinovirus infection and COPD exacerbations. No diagnostic test is available for viral exacerbations of COPD. Increased concentrations of interferon-γ-inducible protein 10 in serum was useful in one study to identify rhinovirus infection in patients with COPD. 71 The presence of fever has also been associated with virus detection during exacerbations. 72 

Although COPD is a lung disease, it is associated with systemic manifestations and comorbid conditions. 73, 74 The most common comorbidities are ischaemic heart disease, diabetes, skeletal muscle wasting, cachexia, osteoporosis, depression, and lung cancer (fi gure 4). 73 These comorbidities aff ect health outcomes, increase the risks of admission to hospital and death, and account for more than 50% of use of health-care resources for COPD. 75, 76 They also explain why clinical features in patients with COPD do not correlate well with FEV₁. 77 These chronic diseases can develop in patients with or without COPD, but their frequent association with the disorder-certainly with severe disease-suggests common risk factors and mechanistic pathways. For instance, cigarette smoking is a major risk for COPD and cardiovascular disease, osteoporosis, and lung cancer. 78 Abundant evidence shows that physical inactivity, which is frequently observed in people who develop COPD, 79 is linked to the major comorbidities. 80, 81 Finally, ageing is a major risk factor for 82 and for COPD in particular a cluster analysis indicated that age rather than FEV₁ accounted for most of the comorbidities and symptoms. 83 One common denominator across comorbidities is systemic infl ammation. Increased concentrations of circulating cytokines (tumour necrosis factor α and interleukins 6 and 8), adipokines (leptin, ghrelin), and acute-phase proteins (C-reactive protein, fi brinogen) are seen in most of the diseases. Furthermore, all described risk factors have been directly linked to the presence of systemic infl ammation. [84] [85] [86] In several studies biomarkers of systemic infl ammation have been seen in patients with COPD, particularly when disease is severe and during acute exacerbations. 87 Whether these systemic markers spill over from the lungs into the systemic circulation or merely refl ect the proinfl ammatory state is unclear. 84, 88, 89 Clinical management

The most widely applied guideline for treatment is the GOLD guideline (table) . 1 For all patients, smoking cessation, reduction in exposure to environmental and occupational risk factors, and yearly infl uenza vaccinations are recommended. The fi rst step must be smoking cessation. This intervention lessens the decline of FEV₁ by about 35 mL per year, 90,91 which slows disease progression and lowers mortality by 18%. 92 Inhaled bronchodilators are the mainstay treatment for COPD (table) . For very severe disease (GOLD stage 4) surgical options include lung trans plantation and lung-volume reduction if quality of life is unacceptably low. Respiratory rehabilitation should be considered at all stages (table) in patients with muscle weakness, deconditioning, and poor quality of life. This treatment should be aimed at improving quality of life and exercise capacity. [93] [94] [95] Two large-scale, long-term, landmark studies have confi rmed the effi cacy of a fi xed combination of a long-acting β 2 agonist (salmeterol) and inhaled corticosteroid (fl uticasone) 96 and a long-acting anticholinergic agent (tiotropium). 97 The two regimens had similar eff ects on prebronchodilator and postbronchodilator FEV₁ (increases of 87-103 mL and 47-92 mL, respectively), scores on the St George's respiratory questionnaire for health status (reductions of three units), and the frequency of exacerbations (reductions of 14-25%). The eff ects of tiotropium seemed smaller, but might be explained by the use of other active treatments: up to 74% of the patients took long-acting β 2 agonists, inhaled corticosteroids, or both. 97 Greater eff ects on health status and frequency of exacerbations in patients receiving tiotropium versus placebo had been reported previously. [98] [99] [100] A direct comparison of a fi xed combination and tiotropium confi rmed similar eff ects on the frequency of exacerbations, but the eff ect on health status was slightly larger with the combined therapy. 101 Inhaled medications used for the treatment of COPD have good safety profi les. Typical side-eff ects of inhaled anticholinergics are dry mouth and prostatism, 102 and for inhaled steroids are skin bruising 103 ocular eff ects, and osteoporosis. 104 β 2 agonists are associated with tremor and cardiac eff ects. 104 Cardiovascular side-eff ects of tiotropium and ipratropium were reported in a metaanalysis by Singh and colleagues, 105 but this fi nding was not confi rmed in a trial of tiotropium 106 and a later review of all tiotropium trials. 102 The latter was accepted as suffi cient proof of the absence of toxic eff ects by the US Food and Drug Administration. 107 A fi xed combination of β 2 agonists and inhaled steroids has been associated with the risk of pneumonia. 96, [108] [109] [110] [111] [112] This risk does not seem to be present with budesonide, 113 although the reason for this discrepancy is unclear. Several issues related to the treatment of COPD are the subjects of debate. The most important is probably whether bronchodilators, inhaled corticosteroids, or both, modify the disease course. No direct evidence clearly shows a disease-modifying role, but circumstantial evidence is accumulating. Two large landmark trials have shown a trend for reduced mortality with fi xed combinations 96 and signifi cantly reduced mortality was seen with a long-acting anti-cholinergic agent in two analyses, although this eff ect was not seen in a third analysis. 97 A post-hoc analysis showed a signifi cant reduction in the decline of FEV₁, by 16 mL per year, with fi xed combinations, 114 and a prespecifi ed subgroup analysis showed a reduction of 6 mL per year with a long-acting anticholinergic agent in patients with GOLD stage 2 COPD. 115 In the latter analysis most of the patients in the control group were taking a combination of a long-acting β 2 agonists and an inhaled steroid and, therefore, these eff ects on annual rate of decline seem to be additive. Thus, with the appropriate combination of agents, tangible eff ects might be obtained. In a smaller subgroup of patients who took no maintenance medications at the beginning of the trial, tiotropium slowed the rate of decline in postbronchodilator FEV₁ by 11 mL per year and of deterioration in health-related quality of life by two-thirds. 116 Finally, safety data indicate that reductions in the incidence of respiratory failure and myocardial infarction as a serious adverse events have been seen with tiotropium. 97 Another question of great interest is whether early pharmacotherapy-when disease is in GOLD stages 1 and 2-is warranted in COPD. 117 Again, no direct evidence presently supports this practice because no prospective, randomised, controlled trials have been done. The studies of fi xed combinations and tiotropium mentioned above both showed that the eff ects of pharmacotherapy were similar in patients with GOLD stage 2 COPD and those with more advanced disease. 115, 118 Decline in FEV₁, and hence disease progression, is faster in the early stages of COPD than in the later stages. 90, 96, 97 Early intervention, therefore, seems as though it would be benefi cial. Figure 5 summarises, in a so-called Fletcher-Peto diagram, the data on FEV₁ decline in relation to age from two landmark studies. 117, 119 Although some evidence of a reduced rate of decline in FEV₁ is present in GOLD stage 2 particularly, 116, 118 the lines depicting the decline in FEV₁ in the diff erent GOLD stages are essentially parallel. Thus, how patients would move from GOLD stage 2 to 3, and further to 4, is hard to conceive. Several potential explanations for this pattern may be off ered. First, patients who reach GOLD stages 3-4 have poor pulmonary function at diagnosis (lower intercept). For instance, patients who have low lung function at presentation because of genetic factors or exposure to environmental factors before age 4 years are at increased risk of developing chronic respiratory disease. 4,120 Second, patients who reach GOLD stages 3-4 also have a faster decline earlier in the disease course than patients in whom disease reaches less advanced stages. 90, 115, 118 Finally, comorbidities of COPD arise in the early disease stages. 73, 74 No randomised controlled trials have yet been done to investigate whether treatment with broncho dilators or inhaled corticosteroids reduces the prevalence or severity of comorbidities. Observational studies suggest that statins, β blockers, and angiotensin-converting-enzyme inhibitors improve outcomes and survival, [121] [122] [123] although these studies might be statistically fl awed simply because of their observational nature. 124 A last relevant question is whether continuous treatment with antibiotics is useful in stable COPD. Macrolides, particularly azithromycin, have been the subject of substantial interest in the past 5 years. In one randomised study of long-term erythromycin compared with placebo in patients with COPD, exacerbations were less frequent (35% reduction) and shorter (13 vs 9 days) in the macrolide group. 125 In a randomised study of 1577 patients, treatment with azithromycin for 1 year lowered the risk of an exacerbation by 27% and improved quality of life by 2·8 units on the St George's respiratory questionnaire but caused decrements in hearing more frequently than placebo. 126 Potential eff ects of azithro mycin have been related to increased alveolar macrophage phagocytic function. 127, 128 One study assessed the eff ect of pulse therapy with moxifl oxacin for 5 days every 8 weeks. A 19% reduction in the frequency of exacerbations was seen, 129 but this eff ect requires confi rmation in other studies. Other agents that might be of benefi t in the treatment of COPD include phosphodiesterase inhibitors, such as theophylline, mucolytic agents, and antioxidants. 130 The only eff ect that seems to have been reported is a 21% reduction in the rate of exacerbations with mucolytic agents. 131 This eff ect might be larger in patients only taking short-acting bronchodilators, 132 and is not seen in patients taking inhaled corticosteroids. 133

Several national and international guidelines for the treatment of COPD exacerbations are available. 134, 135 The fi rst step is to increase the dose and frequency of shortacting β 2 agonists, anticholinergic bronchodilators, or both. If no response is noted, oral corticosteroids may be added. If changes are seen in expectorated sputum, antibiotics can be used, and if severity increases, other interventions, such as theophylline, should be considered. Oxygen and ventilatory support is recommended if respiratory failure occurs (fi gure 6). 136 Non-invasive ventilatory support is the fi rst approach to hypercapnic respiratory failure and is eff ective in avoiding intubation and reducing the risk of death. 137 Cochrane reviews support the use of short-acting bronchodiolators, 138 systemic corticosteroids, 139 anti biotics, 140 and non-invasive ventilation, 137 and a meta-analysis supports the use of theophylline. 141 Besides these respiratory treatments, the complexity (eg, associated with pneumonia, heart failure, or pneumothorax) need to be taken into account and comorbidities need to be treated appropriately.

Substantial unmet needs remain in COPD and improved insight is required into the pathophysiology and eff ective treatments. From a diagnostic point of view, specifi c disease biomarkers, improved methods for early detection and diagnosis of exacerbations, and enhanced understanding of the relations between COPD and comorbidities would be helpful. Additionally, an important question that so far remains unanswered is whether diff erent phenotypes of the disease exist and, if so, whether they respond diff erently to treatment.

Research is being done into new compounds to treat COPD. 142 Rofl umilast, an oral specifi c phosphodiesterase 4 inhibitor, improved postbronchodilator FEV₁ by about 48 mL and was associated with a 17% reduction in the frequency of exacerbations in patients with GOLD stage 3-4 COPD and history of exacerbations, cough, and sputum changes, but had no eff ect on health-related quality of life or systemic infl ammation. 143 Similar eff ects were seen in patients who received rofl umilast in addition to salmeterol or tiotropium. 144 Indacaterol is a new, once-daily, longacting β 2 agonist that provides sustained bronchodilation with an acceptable safety profi le. 145, 146 Improvements in FEV₁ of 160-170 mL have been reported and discussed. 145 Several new, once-daily, long-acting anticholinergic agents and β 2 agonists are under development and being tested alone and in combination, with each other and with oncedaily inhaled steroids. Additionally, agents that possess simultaneous anticholinergic and β 2 -agonist activities (muscarinic antagonist β 2 agonists) are being devel oped. 147 These latter agents will probably improve symptomatic control, but it seems unlikely that they will modify disease substantially more than available agents. By contrast, enhanced disease modifi cation is expected from a range of novel infl ammatory blockers that includes inhibitors of phosphodiesterase 4, agents targeting CD8+ T cells, 142 and inhibitors of NF-κB, 142 chemokine-receptors 2 and 3, 142, 148 T-helper-17 cells, 142 and MAP kinase p38. 142, 149 Interest has been shown in the role of the vitamin D pathway in chronic diseases in general and in COPD in particular. 150, 151 In one study a high prevalence of vitamin D defi ciency was found and variants in the vitamin-Dbinding gene (GC) correlated with vitamin D levels and the risk of COPD. 152 Impaired macrophage function, which improves after vitamin D supplementation, is probably related to the development of COPD. 128 Randomised controlled trials are being done to assess the eff ects of vitamin D supplementation on the disease course of COPD (ClinicalTrials.gov NCT00977873). 153 In the fi rst of these studies, vitamin D supplementation did not reduce COPD exacerbations in the whole study population, but it did in a subgroup with low vitamin D levels (<10 ng/mL) at baseline. 153 Finally, entirely new care models need to be developed for patients with COPD as well as other chronic diseases. In view of the comorbidities frequently seen in patients with COPD, new models for multidisciplinary care, clinical pathways, self-management, 154 teleconsultating, 155 telemonitoring, and rehabilitation 99 are required. In studies the latter four modalities have been associated with clear eff ects on outcomes, but access to these services remains poor-for instance, rehabilitation is applied to less than 5% of the eligible patients. 99, 153, 154 

Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study

Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities

Prevalence and predictors of undiagnosed chronic obstructive pulmonary disease in a Norwegian adult general population

Chronic obstructive pulmonary disease surveillance-United States

Early life origins of chronic obstructive pulmonary disease

An offi cial American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease

Mechanisms of emphysema in α 1 -antitrypsin defi ciency: molecular and cellular insights

Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function

A genome-wide association study in chronic obstructive pulmonary disease (COPD): identifi cation of two major susceptibility loci

A genome-wide association study of pulmonary function measures in the Framingham Heart Study

MMP12, lung function, and COPD in high-risk populations

The 15q24/25 susceptibility variant for lung cancer and chronic obstructive pulmonary disease is associated with emphysema

Hyperinfl ation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease

The pathology of chronic obstructive pulmonary disease

What drives the peripheral lung-remodeling process in chronic obstructive pulmonary disease?

New paradigms in the pathogenesis of chronic obstructive pulmonary disease I

Genetics and genomics of chronic obstructive pulmonary disease

Immunologic aspects of chronic obstructive pulmonary disease

Innate immune recognition in infectious and noninfectious diseases of the lung

Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease: molecular and cellular mechanisms

Oxidative stress and redox regulation of lung infl ammation in COPD

Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema

Cigarette smoke-induced emphysema: a role for the B cell?

Antielastin autoimmunity in tobacco smoking-induced emphysema

Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD: updated

International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study

Global burden of COPD: risk factors, prevalence, and future trends

Chronic obstructive pulmonary disease in fi ve Latin American cities (the PLATINO study): a prevalence study

Trends in the leading causes of death in the United States

Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario

Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997-2007

Global burden of COPD: systematic review and meta-analysis

The Foxp3 + regulatory T cell: a jack of all trades, master of regulation

Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking

T H 17 cells in asthma and COPD

T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients

Alveolar cell senescence in patients with pulmonary emphysema

Cigarette smoke induces senescence in alveolar epithelial cells

COPD as a disease of accelerated lung aging

Role of lung maintenance program in the heterogeneity of lung destruction in emphysema

Stem cells are dispensable for lung homeostasis but restore airways after injury

Cigarette smoke inhibits alveolar repair: a mechanism for the development of emphysema

Epithelial repair mechanisms in the lung

Association between lung function and exacerbation frequency in patients with COPD

Susceptibility to exacerbation in chronic obstructive pulmonary disease

Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease

Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease

Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease

Infections and airway infl ammation in chronic obstructive pulmonary disease severe exacerbations

Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD

Bronchoscopic validation of the signifi cance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease

Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy

Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD

Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush

Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease

Infection in the pathogenesis and course of chronic obstructive pulmonary disease

New strains of bacteria and exacerbations of chronic obstructive pulmonary disease

Infl ammatory profi le of new bacterial strain exacerbations of chronic obstructive pulmonary disease

Airway bacterial load and FEV₁ decline in patients with chronic obstructive pulmonary disease

Variability and eff ects of bronchial colonisation in patients with moderate COPD

Relationship between bacterial fl ora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD

Pseudomonas aeruginosa in chronic obstructive pulmonary disease

Evaluation of antimicrobial treatment in mechanically ventilated patients with severe chronic obstructive pulmonary disease exacerbations

Mortality of COPD patients infected with multi-resistant Pseudomonas aeruginosa: a case and control study

Bacterial infection in exacerbated COPD with changes in sputum characteristics

Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease

Experimental Rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation

Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD

Respiratory viral infection in exacerbations of COPD

COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention

Complex chronic comorbidities of COPD

Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD

Mortality in COPD: role of comorbidities

The body-mass index, airfl ow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease

The problem of tobacco smoking

Characteristics of physical activities in daily life in chronic obstructive pulmonary disease

Waging war on modern chronic diseases: primary prevention through exercise biology

Physical activity transitions and chronic disease

Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance

Clinical COPD phenotypes: a novel approach using principal component and cluster analyses

From COPD to chronic systemic infl ammatory syndrome?

Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms

Systemic eff ects of smoking

Raised CRP levels mark metabolic and functional impairment in advanced COPD

Systemic manifestations and comorbidities of COPD

Systemic infl ammation and comorbidity in COPD: a result of 'overspill' of infl ammatory mediators from the lungs? Review of the evidence

Eff ects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV₁. The Lung Health Study

Smoking and lung function of Lung Health Study participants after 11 years

The eff ects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial

Pulmonary rehabilitation for chronic obstructive pulmonary disease

Pulmonary rehabilitation in chronic obstructive pulmonary disease

Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines

Salmeterol and fl uticasone propionate and survival in chronic obstructive pulmonary disease

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

The eff ect of tiotropium on exacerbations and airfl ow in patients with COPD

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fl uticasone propionate or tiotropium bromide

Tiotropium HandiHaler in the treatment of COPD: a safety review

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking

Clinical safety of long-acting β2-agonist and inhaled corticosteroid combination therapy in COPD

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

Cardiovascular safety of tiotropium in patients with COPD

The safety of tiotropiumthe FDA's conclusions

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results

Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease

Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data

Eff ect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

Eff ect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecifi ed subgroup analysis of a randomised controlled trial

Tiotropium as a fi rst maintenance drug in COPD: secondary analysis of the UPLIFT trial

Treatment of COPD: the sooner the better?

Effi cacy of salmeterol/ fl uticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

The natural history of chronic airfl ow obstruction

Lung function and airway diseases

Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease

β-Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease

Eff ect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease

Co-morbidity in COPD: the eff ects of cardiovascular drug therapies

Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations

COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD

Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease

Defective macrophage phagocytosis of bacteria in COPD

Pulsed moxifl oxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial

Mucoactive therapy in COPD

Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease

Eff ect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study

Eff ects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review

Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease

Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease

Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease

Antibiotics for exacerbations of chronic obstructive pulmonary disease

Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials

Immunology of asthma and chronic obstructive pulmonary disease

Rofl umilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

Rofl umilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases

Indacaterol maleate for the treatment of chronic obstructive pulmonary disease

Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review

CC-chemokine receptors in chronic obstructive pulmonary disease

A randomized, placebo-controlled study of the eff ects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of infl ammation in COPD patients

Vitamin D beyond bones in chronic obstructive pulmonary disease: time to act

The vitamin D axis in the lung: a key role for vitamin D-binding protein

Vitamin D defi ciency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene

High doses of vitamin D to reduce exacerbations in COPD: a randomized controlled trial

Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specifi c self-management intervention

Integrated care prevents hospitalisations for exacerbations in COPD patients